Crown Bioscience announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent.
CrownBio will add a significant number of cell lines and reference standards related to EGFR, KRAS, and BRAF signaling cascades of the MAPK pathway, which plays a critical role in the development a...
“The publication of these papers are indicative of how CrownBio continues to further validate the translatability of this model and our commitment to bring to the market novel models that are more ...
OmniScreen™ will be run on a cycled schedule every three months, allowing clients to select from three panels of cell lines that are most suitable for their needs.
1 of 2
Receive JSR Life Sciences news on your RSS reader.